Previous 10 | Next 10 |
2023-06-01 16:40:27 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) has received a formal notice from The Nasdaq stating that it has regained compliance with the $1/share minimum bid price requirement pursuant to Nasdaq Listing Rule. In order to regain compliance, the Co. was r...
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with...
2023-05-23 13:09:12 ET Gainers: CohBar ( CWBR ) +158% . Shuttle Pharmaceuticals ( SHPH ) +121% . Ocean Biomedical ( OCEA ) +108% . HeartCore Enterprises ( HTCR ) +110% . Lifecore Biomedical ( LFCR ) +66% . T Stamp ( IDAI ...
2023-05-15 13:49:08 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) announced a reverse stock split of its outstanding common shares at a ratio of 1-for-20, effective as of 5:00 p.m. ET on May 15, 2023. The reverse stock split was approved by the Company’s stockholders at it...
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ...
2023-05-12 02:59:46 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) enter agreement to sell two of its sGC stimulator assets in exchange for cash and equity ownership to a new private company. Investors will park $81M to develop zagociguat to treat MELAS* and other diseases ass...
Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in exchange for its zagociguat and CY3018 assets Definitive agre...
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers p...
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent and disinterested members (the “Independent Board”), has reviewed a non-binding propos...
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designatio...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a de...